NVIC.org (@NVIC)

FDA Plans for Expedited Licensure Approval of GSK’s Autism Drug | TVR | Amber Baker The FDA expedited the licensing process by invoking a rarely used regulatory provision to reinstate GSK’s original approval application and request a label update adding cerebral folate deficiency (CFD), based on its own review of 40 patient cases published between 2009 and 2024. 🔹FDA’s Timeline Expands Access to Autism Symptom Treatment 🔹Drug Demand Surges After White House Press Conference and Reports of Successful Treatment of Autistic Children 🔹Plans to Overhaul Federal Vaccine Injury Compensation Program Read. Comment. Share. ➡️ https://thevaccinereaction.org/2025/10/fda-plans-for-expedited-licensure-approval-of-gsks-autism-drug/ #Autism #CFD #Leucovorin #TheVaccineReaction #NVIC